Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00034
|
|||||
| Drug Name |
Creatine ALS-08
|
|||||
| Synonyms |
AL-02 (ALS), Avicena; AL-08 (ALS), Avicena; ALS-02; ALS-05; ALS-08; Creatine; Creatine (ALS), Avicena; Creatine (Huntington's disease), Avicena; Creatine (Parkinson's disease), Avicena; Creatine (amyotrophic lateral sclerosis), Avicena; HD-02; PD-01, Avicena; PD-02; PD-04; PD-06
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Motor neurone disease [ICD11:8B60] | Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C4H9N3O2
|
|||||
| Canonical SMILES |
CN(CC(=O)O)C(=N)N
|
|||||
| InChI |
InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)
|
|||||
| InChIKey |
CVSVTCORWBXHQV-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 57-00-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 131.13 | Topological Polar Surface Area | 90.4 | ||
| Heavy Atom Count | 9 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
-1.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
102851574
,103187076
,104295252
,10527747
,117475574
,117475575
,125292581
,125326843
,125353363
,126522989
,126677726
,127265156
,127265157
,127265158
,127265159
,127265160
,127265161
,127684899
,131999723
,134970539
,136961253
,137003471
,15170675
,24438948
,24857517
,24892273
,3139605
,3594
,46504868
,4947662
,50800367
,56311485
,56311510
,56312867
,56365626
,57320315
,57410916
,74369
,7886773
,81065541
,8137931
,8143593
,8150697
,831847
,85164924
,855190
,87457515
,87565524
,88828666
,93620616
|
|||||
| ChEBI ID |
ChEBI:16919
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | CRTR | Transporter Info | Creatine transporter 1 | Substrate | [2] | |
| MCT12 | Transporter Info | Monocarboxylate transporter 12 | Substrate | [3] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00098956) Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance Training | |||||
| 2 | Astrocytic -aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. 2018 Feb;113:1-7. | |||||
| 3 | Mutation in the Monocarboxylate Transporter 12 Gene Affects Guanidinoacetate Excretion but Does Not Cause Glucosuria. J Am Soc Nephrol. 2016 May;27(5):1426-36. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.